Brief: Achilles Therapeutics Plc Receives Nasdaq Deficiency Letter
24/04/2023 23:27
April 24 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS PLC - ON APRIL 21, CO RECEIVED A
DEFICIENCY LETTER FROM NASDAQ
Source text : (https://bit.ly/40zJv02)
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement